Skin cancer: a vaccine could reduce the risk of death by 44%, according to a preliminary test | Estadão Mobility

“It’s a technology similar to the vaccines against covid-19, which allows new vaccines to be created quickly from different antigens. But in this case, the personalization is done from patient to patient and not in bulk, as we do it with updated doses against covid. In addition, cancer cells do not mutate as quickly as the virus”, explains Márcia Abade, medical director of MSD Brasil.

So far, the tests have been performed on 157 patients with stage III and IV melanoma who underwent complete surgical resection. In 2023, the vaccine will undergo a final testing phase – which should have a larger group of patients and last around two to three years. If it proves effective and safe, it will be marketed.

Personalization and Precision in Cancer Care — To develop the vaccine, the pharmaceutical company uses a biopsy of the patient as the basis, in which the antigens of this tumor are detected and develops the personalized vaccine. “We perform a genetic analysis and design a specific and individualized vaccine for this patient,” adds Márcia Abade. With this, according to the doctor, the chances of effectiveness tend to be greater.

The approval of the test vaccine could be a first step towards the use of this technology for other types of cancers, points out Stéphane Bancel, CEO of Moderna.

“We will initiate additional studies in melanoma and other forms of cancer with the goal of providing patients with truly individualized cancer care,” she says. “We look forward to publishing the full data and sharing the results at an upcoming oncology medical conference, as well as with health authorities.”


Add Comment